RG
IONS icon

Redmile Group’s Ionis Pharmaceuticals IONS Stock Holding History

Redmile Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-266,187
Closed -$10.1M – 78
2022
Q4 		$10.1M Sell
266,187
-141,472
-35% -$5.95M 0.41% 46
2022
Q3 		$18M Buy
+407,659
New +$17.2M 0.7% 41

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Redmile Group's IONS Position: Q1 2023 in Review

Redmile Group sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 266,187 shares — an estimated $10.1M sold.

Redmile Group first reported a position in IONS in Q3 2022 and held it in 2 quarters. The position peaked at $18M in Q3 2022. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • Redmile Group reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Redmile Group sold 266,187 Ionis Pharmaceuticals shares in Q1 2023, an estimated $10.1M.
  • Redmile Group first reported a position in Ionis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Redmile Group's Ionis Pharmaceuticals position peaked at $18M in Q3 2022.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.